The telehealth industry is rapidly experimenting with GLP-1 receptor agonists as an off-label treatment for addiction, effectively moving faster than regulatory frameworks can evaluate safety and efficacy. This development highlights a growing tension in digital health: the ability to scale interventions quickly often outpaces the clinical evidence and oversight mechanisms designed to protect patients.
The phenomenon reflects a broader pattern in telehealth where entrepreneurs and providers see therapeutic potential in existing medications and move to deploy them before formal FDA approval for new indications. GLP-1s, originally developed for diabetes and later approved for weight management, are now being prescribed through virtual channels for opioid and alcohol use disorders based on preliminary research and clinical intuition rather than large-scale controlled trials. This represents a calculated bet that the drugs work—and that waiting for traditional approval pathways is unnecessary.
The Liability and Fragmentation Problem
For health system leaders and IT vendors, this trend creates substantial operational and legal concerns. When telehealth platforms prescribe off-label medications, responsibility for adverse outcomes becomes murky. If a patient experiences cardiac complications, metabolic side effects, or psychological reactions not yet documented in addiction treatment populations, who bears liability—the platform, the prescriber, or the patient's primary care physician who may be unaware of the regimen?
More critically, off-label GLP-1 prescribing through telehealth often occurs in isolation from integrated care ecosystems. A patient receiving an appetite-suppressing GLP-1 through a stand-alone telehealth app may simultaneously see a primary care doctor, psychiatrist, and addiction specialist—none of whom have real-time visibility into the full medication picture. This fragmentation increases the risk of drug interactions, duplicative prescribing, and missed opportunities for coordinated behavioral therapy, which remains foundational to addiction treatment success.
Health systems investing in interoperability infrastructure and electronic health records face pressure to integrate data from these parallel telehealth channels. The result is reactive compliance work rather than proactive clinical governance.
For vendors, the situation creates both opportunity and risk. Companies that can build robust tracking systems for off-label prescribing, patient consent workflows, and clinical decision support tools for addiction specialists may find demand. Conversely, vendors whose platforms facilitate fragmented care without adequate safeguards face reputational and regulatory exposure.
The FDA's current stance—essentially allowing the market to move first—suggests regulators are stretched. Agency leadership may believe that monitoring real-world outcomes from telehealth GLP-1 prescribing provides valuable data, or they may lack resources to intervene. Either way, the burden of ensuring patient safety has shifted from pre-market approval to post-market surveillance, a less reliable mechanism.
What matters most for health system executives is establishing clear protocols now: requiring telehealth partners to report off-label prescribing into central registries, mandating integration with primary care records, and developing guidelines about which patient populations—if any—should receive experimental GLP-1 regimens. Health systems should also demand that telehealth vendors maintain detailed adverse event tracking and contribute to registries that help the medical community understand real-world safety profiles.
The telehealth industry's enthusiasm for repurposing GLP-1s reflects genuine clinical curiosity and market demand. But without deliberate governance, it risks creating a parallel healthcare system where innovation outpaces accountability—exactly the opposite of what patients with addiction disorders deserve.
Reporting basis: statnews.com. Analysis by the HTC editorial desk.